Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Mesothelioma data at ASCO 2020

Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, highlights data coming from the RAMES study (NCT03560973) which evaluated the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in patients with relapsed, advanced mesothelioma. Dr Shah also highlights data coming from other recent studies in mesothelioma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).